Polymeric conjugates for drug delivery.

The field of polymer therapeutics has evolved over the past decade and has resulted in the development of polymer-drug conjugates with a wide variety of architectures and chemical properties. Whereas traditional non-degradable polymeric carriers such as poly(ethylene glycol) (PEG) and N-(2-hydroxypropyl methacrylamide) (HPMA) copolymers have been translated to use in the clinic, functionalized polymer-drug conjugates are increasingly being utilized to obtain biodegradable, stimuli-sensitive, and targeted systems in an attempt to further enhance localized drug delivery and ease of elimination. In addition, the study of conjugates bearing both therapeutic and diagnostic agents has resulted in multifunctional carriers with the potential to both "see and treat" patients. In this paper, the rational design of polymer-drug conjugates will be discussed followed by a review of different classes of conjugates currently under investigation. The design and chemistry used for the synthesis of various conjugates will be presented with additional comments on their potential applications and current developmental status.

[1]  A. Ray,et al.  HPMA Copolymer-Aminohexylgeldanamycin Conjugates Targeting Cell Surface Expressed GRP78 in Prostate Cancer , 2010, Pharmaceutical Research.

[2]  K. Ulbrich,et al.  HPMA copolymers with pH-controlled release of doxorubicin: in vitro cytotoxicity and in vivo antitumor activity. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[3]  C. Peterson,et al.  Antitumor efficacy of colon-specific HPMA copolymer/9-aminocamptothecin conjugates in mice bearing human-colon carcinoma xenografts. , 2009, Macromolecular bioscience.

[4]  Q. Teng,et al.  Design and evaluation of micellar nanocarriers for 17-allyamino-17-demethoxygeldanamycin (17-AAG). , 2010, International journal of pharmaceutics.

[5]  N. K. Jain,et al.  Dendrimers as therapeutic agents: a systematic review , 2009 .

[6]  Paul Debbage,et al.  Targeted drugs and nanomedicine: present and future. , 2009, Current pharmaceutical design.

[7]  P. Zahedi,et al.  Polymeric drug delivery systems for localized cancer chemotherapy , 2010, Drug delivery.

[8]  Tongwen Xu,et al.  Design of biocompatible dendrimers for cancer diagnosis and therapy: current status and future perspectives. , 2011, Chemical Society reviews.

[9]  A. Tolcher,et al.  A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Simona Jevševar,et al.  PEGylation of therapeutic proteins , 2010, Biotechnology journal.

[11]  Alexander V Kabanov,et al.  Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[12]  Kazunori Kataoka,et al.  Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property: tumor permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy. , 2005, Bioconjugate chemistry.

[13]  S. Perrier,et al.  Bioapplications of RAFT polymerization. , 2009, Chemical reviews.

[14]  Xue Ying,et al.  PEGylated Poly(amidoamine) dendrimer-based dual-targeting carrier for treating brain tumors. , 2011, Biomaterials.

[15]  V. Torchilin,et al.  Micellar Nanocarriers: Pharmaceutical Perspectives , 2006, Pharmaceutical Research.

[16]  Jonathan R. McDaniel,et al.  Drug delivery to solid tumors by elastin-like polypeptides. , 2010, Advanced drug delivery reviews.

[17]  J. Kopeček,et al.  Coiled-coil based drug-free macromolecular therapeutics: in vivo efficacy. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[18]  R. Kannan,et al.  Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications. , 2010, Drug discovery today.

[19]  A. Ray,et al.  Comparison of active and passive targeting of docetaxel for prostate cancer therapy by HPMA copolymer-RGDfK conjugates. , 2011, Molecular pharmaceutics.

[20]  Vladimir P Torchilin,et al.  Passive and active drug targeting: drug delivery to tumors as an example. , 2010, Handbook of experimental pharmacology.

[21]  Lei Yu,et al.  Synthesis, characterization, and biological evaluation of poly(L-γ-glutamyl-glutamine)- paclitaxel nanoconjugate , 2010, International journal of nanomedicine.

[22]  S. Balu-Iyer,et al.  Delivery of therapeutic proteins. , 2010, Journal of pharmaceutical sciences.

[23]  Michael B. Hall,et al.  Dendritic macromolecules: synthesis of starburst dendrimers , 1986 .

[24]  J. Schellens,et al.  Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel , 2001, Anti-cancer drugs.

[25]  Francesco M Veronese,et al.  Anti-cancer PEG-enzymes: 30 years old, but still a current approach. , 2008, Advanced drug delivery reviews.

[26]  H. Dai,et al.  PEG branched polymer for functionalization of nanomaterials with ultralong blood circulation. , 2009, Journal of the American Chemical Society.

[27]  H. Ghandehari,et al.  HPMA copolymer-cyclic RGD conjugates for tumor targeting. , 2010, Advanced drug delivery reviews.

[28]  U. Schubert,et al.  Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. , 2010, Angewandte Chemie.

[29]  Atsushi Harada,et al.  Design of environment-sensitive supramolecular assemblies for intracellular drug delivery: polymeric micelles that are responsive to intracellular pH change. , 2003, Angewandte Chemie.

[30]  Michael Jay,et al.  Polymer Micelles with Hydrazone-Ester Dual Linkers for Tunable Release of Dexamethasone , 2011, Pharmaceutical Research.

[31]  Y. Shaked,et al.  Antiangiogenic antitumor activity of HPMA copolymer-paclitaxel-alendronate conjugate on breast cancer bone metastasis mouse model. , 2011, Molecular pharmaceutics.

[32]  R. Fram,et al.  XMT-1001, a novel polymeric camptothecin pro-drug in clinical development for patients with advanced cancer. , 2009, Advanced drug delivery reviews.

[33]  F. Veronese,et al.  PEGylation for improving the effectiveness of therapeutic biomolecules. , 2009, Drugs of today.

[34]  M. Socinski,et al.  Randomized Phase III Trial Comparing Single-Agent Paclitaxel Poliglumex (CT-2103, PPX) with Single-Agent Gemcitabine or Vinorelbine for the Treatment of PS 2 Patients with Chemotherapy-Naïve Advanced Non-small Cell Lung Cancer , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[35]  K. Fu,et al.  Synthesis and Evaluation of a Well-defined HPMA Copolymer–Dexamethasone Conjugate for Effective Treatment of Rheumatoid Arthritis , 2008, Pharmaceutical Research.

[36]  A. Ray,et al.  PAMAM-Camptothecin Conjugate Inhibits Proliferation and Induces Nuclear Fragmentation in Colorectal Carcinoma Cells , 2010, Pharmaceutical Research.

[37]  H. Ghandehari,et al.  Transepithelial transport and toxicity of PAMAM dendrimers: implications for oral drug delivery. , 2012, Advanced drug delivery reviews.

[38]  Scott H. Medina,et al.  Dendrimers as carriers for delivery of chemotherapeutic agents. , 2009, Chemical reviews.

[39]  S. Wołowiec,et al.  Solubility and in vitro transdermal diffusion of riboflavin assisted by PAMAM dendrimers. , 2011, International journal of pharmaceutics.

[40]  Kinam Park,et al.  Targeted drug delivery to tumors: myths, reality and possibility. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[41]  H. Ghandehari,et al.  A prostate-specific antigen–activated N-(2-hydroxypropyl) methacrylamide copolymer prodrug as dual-targeted therapy for prostate cancer , 2007, Molecular Cancer Therapeutics.

[42]  Yiguang Jin,et al.  A 5-fluorouracil-loaded pH-responsive dendrimer nanocarrier for tumor targeting. , 2011, International journal of pharmaceutics.

[43]  Bo Yu,et al.  Receptor-targeted nanocarriers for therapeutic delivery to cancer , 2010, Molecular membrane biology.

[44]  C. van Nostrum,et al.  Synthesis and applications of biomedical and pharmaceutical polymers via click chemistry methodologies. , 2009, Bioconjugate chemistry.

[45]  T. Lammers Improving the efficacy of combined modality anticancer therapy using HPMA copolymer-based nanomedicine formulations. , 2010, Advanced drug delivery reviews.

[46]  W. Guo,et al.  Endosomal pH-activatable poly(ethylene oxide)-graft-doxorubicin prodrugs: synthesis, drug release, and biodistribution in tumor-bearing mice. , 2011, Biomacromolecules.

[47]  K. Ulbrich,et al.  New HPMA copolymer-based drug carriers with covalently bound hydrophobic substituents for solid tumour targeting. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[48]  J. Singer,et al.  Biological and clinical characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymer–drug conjugate , 2006, International journal of nanomedicine.

[49]  Y. Bae,et al.  Reconstitutable charged polymeric (PLGA)(2)-b-PEI micelles for gene therapeutics delivery. , 2011, Biomaterials.

[50]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.

[51]  J. Schellens,et al.  A Phase I and Pharmacological Study of the Platinum Polymer AP5280 Given as an Intravenous Infusion Once Every 3 Weeks in Patients with Solid Tumors , 2004, Clinical Cancer Research.

[52]  Thommey P. Thomas,et al.  Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. , 2005, Cancer research.

[53]  K. Ulbrich,et al.  Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers. , 2009, Biomaterials.

[54]  V. Torchilin,et al.  Poly(malic acid) nanoconjugates containing various antibodies and oligonucleotides for multitargeting drug delivery. , 2008, Nanomedicine.

[55]  Reynier Báez,et al.  PEGylated Interferon-α2b: A Branched 40K Polyethylene Glycol Derivative , 2005, Pharmaceutical Research.

[56]  Vladimir Torchilin,et al.  Multifunctional and stimuli-sensitive pharmaceutical nanocarriers. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[57]  D. Kerr,et al.  Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[58]  J. Kopeček,et al.  Liberation of doxorubicin from HPMA copolymer conjugate is essential for the induction of cell cycle arrest and nuclear fragmentation in ovarian carcinoma cells. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[59]  J. Haveman,et al.  The relevance of tumour pH to the treatment of malignant disease. , 1984, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[60]  A. Secord,et al.  A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study. , 2008, Gynecologic oncology.

[61]  R. J. Green,et al.  Polymer-drug conjugates for combination anticancer therapy: investigating the mechanism of action. , 2009, Journal of medicinal chemistry.

[62]  Aaron D Baldwin,et al.  Polysaccharide‐modified synthetic polymeric biomaterials , 2010, Biopolymers.

[63]  Andrew Becker,et al.  Methotrexate delivery via folate targeted dendrimer-based nanotherapeutic platform. , 2009, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[64]  W. Hennink,et al.  A novel family of L-amino acid-based biodegradable polymer-lipid conjugates for the development of long-circulating liposomes with effective drug-targeting capacity. , 2003, Bioconjugate chemistry.

[65]  James R. Dewald,et al.  A New Class of Polymers: Starburst-Dendritic Macromolecules , 1985 .

[66]  M. Hershfield,et al.  Adenosine deaminase deficiency with late onset of recurrent infections: response to treatment with polyethylene glycol-modified adenosine deaminase. , 1988, The Journal of pediatrics.

[67]  D. Tomalia,et al.  Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. , 2001, Drug discovery today.

[68]  J. Schellens,et al.  Phase I and pharmacokinetic trial of AP5346, a DACH–platinum–polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients , 2007, Cancer Chemotherapy and Pharmacology.

[69]  H. Maeda,et al.  Exploiting the enhanced permeability and retention effect for tumor targeting. , 2006, Drug discovery today.

[70]  Jean M. J. Fréchet,et al.  Dendrimers and supramolecular chemistry , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[71]  Andrew T. Russell,et al.  Self-immolative linkers in polymeric delivery systems , 2011 .

[72]  M. Zamai,et al.  Polymer-bound camptothecin: initial biodistribution and antitumour activity studies. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[73]  Zhi-xin Xu,et al.  Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. , 2001, Bioconjugate chemistry.

[74]  Ruixia Chen,et al.  Degradation and degradation-induced re-assembly of PVP-PCL micelles. , 2010, Biomacromolecules.

[75]  C. van Nostrum,et al.  Micelles based on HPMA copolymers. , 2010, Advanced drug delivery reviews.

[76]  H. Groen,et al.  A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours , 2004, British Journal of Cancer.

[77]  Ruth Duncan,et al.  Development of HPMA copolymer-anticancer conjugates: clinical experience and lessons learnt. , 2009, Advanced drug delivery reviews.

[78]  John Samuel,et al.  Poly(ethylene oxide)-block-poly(L-amino acid) micelles for drug delivery. , 2002, Advanced drug delivery reviews.

[79]  Thommey P. Thomas,et al.  Poly(amidoamine) dendrimer-based multifunctional engineered nanodevice for cancer therapy. , 2005, Journal of medicinal chemistry.

[80]  Kazunori Kataoka,et al.  Block copolymer micelles for delivery of gene and related compounds. , 2002, Advanced drug delivery reviews.

[81]  Véronique Préat,et al.  To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[82]  Deborah S. Goldberg,et al.  G3.5 PAMAM dendrimers enhance transepithelial transport of SN38 while minimizing gastrointestinal toxicity. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[83]  Hisataka Kobayashi,et al.  Dendrimer-based contrast agents for molecular imaging. , 2008, Current topics in medicinal chemistry.

[84]  V. Šubr,et al.  Cleavage of oligopeptide side-chains in N-(2-hydroxypropyl)meth-acrylamide copolymers by mixtures of lysosomal enzymes☆ , 1988 .

[85]  H. Ringsdorf Structure and properties of pharmacologically active polymers , 1975 .

[86]  M. Vicent,et al.  Do HPMA copolymer conjugates have a future as clinically useful nanomedicines? A critical overview of current status and future opportunities. , 2010, Advanced drug delivery reviews.

[87]  Y. Tsutsumi,et al.  Antitumor Activity of Tumor Necrosis Factor-α Conjugated with Polyvinylpyrrolidone on Solid Tumors in Mice , 2000 .

[88]  J. Feijen,et al.  α-Amino acid containing degradable polymers as functional biomaterials: rational design, synthetic pathway, and biomedical applications. , 2011, Biomacromolecules.

[89]  Karl Fischer,et al.  Temperature triggered self-assembly of polypeptides into multivalent spherical micelles. , 2008, Journal of the American Chemical Society.

[90]  J. Kopeček,et al.  Synthesis of Biodegradable Multiblock Copolymers by Click Coupling of RAFT-Generated HeterotelechelicPolyHPMA Conjugates. , 2011, Reactive & functional polymers.

[91]  J. Kopeček Controlled biodegradability of polymers--a key to drug delivery systems. , 1984, Biomaterials.

[92]  Hiroshi Maeda,et al.  Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. , 2010, Bioconjugate chemistry.

[93]  Y. Pommier DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition. , 2009, Chemical reviews.

[94]  Michel Vert,et al.  Peptide-poly(L-lysine citramide) conjugates and their in vitro anti-HIV behavior. , 2009, Biomacromolecules.

[95]  H. Maeda,et al.  Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[96]  P. Shewry,et al.  Elastomeric proteins: biological roles, structures and mechanisms. , 2000, Trends in biochemical sciences.

[97]  J. Kemp,et al.  Inhibition of lymphoma growth in vivo by combined treatment with hydroxyethyl starch deferoxamine conjugate and IgG monoclonal antibodies against the transferrin receptor. , 1995, Cancer research.

[98]  David Putnam,et al.  Polymer conjugates with anticancer activity , 1995 .

[99]  Jun Fang,et al.  The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. , 2011, Advanced drug delivery reviews.

[100]  J. Kopeček,et al.  Enhanced antitumor activity of combinations of free and HPMA copolymer-bound drugs. , 2008, International journal of pharmaceutics.

[101]  Lei Zhu,et al.  Synthesis and in vitro cancer cell targeting of folate-functionalized biodegradable amphiphilic dendrimer-like star polymers. , 2010, Biomacromolecules.

[102]  L. Gerweck,et al.  Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer. , 1996, Cancer research.

[103]  C. Takimoto,et al.  Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies , 2009, Cancer Chemotherapy and Pharmacology.

[104]  F. Szoka,et al.  A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas , 2006, Proceedings of the National Academy of Sciences.

[105]  J. Kopeček,et al.  Synthesis and characterization of poly(ε-caprolactone)-block-poly[N-(2-hydroxypropyl)methacrylamide] micelles for drug delivery. , 2011, Macromolecular bioscience.

[106]  Y. Chau,et al.  Synthesis, characterization, and in vivo evaluation of poly(ethylene oxide-co-glycidol)-platinate conjugate. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[107]  E. Sausville,et al.  Biodistribution of HPMA copolymer-aminohexylgeldanamycin-RGDfK conjugates for prostate cancer drug delivery. , 2009, Molecular pharmaceutics.

[108]  S. Jain,et al.  A PEGylated dendritic nanoparticulate carrier of fluorouracil. , 2003, International journal of pharmaceutics.

[109]  Krzysztof Matyjaszewski,et al.  Nanostructured functional materials prepared by atom transfer radical polymerization , 2009, Nature Chemistry.

[110]  M. Vicent,et al.  HPMA Copolymer-1,5-Diazaanthraquinone Conjugates as Novel Anticancer Therapeutics , 2004, Journal of drug targeting.

[111]  Malar A. Azagarsamy,et al.  Guest-release control in enzyme-sensitive, amphiphilic-dendrimer-based nanoparticles through photochemical crosslinking. , 2011, Chemistry.

[112]  V. Pillay,et al.  Stimuli-responsive polymers and their applications in drug delivery , 2009, Biomedical materials.

[113]  Gianfranco Pasut,et al.  PEG conjugates in clinical development or use as anticancer agents: an overview. , 2009, Advanced drug delivery reviews.

[114]  N. Vorsa,et al.  Dendrimer versus linear conjugate: Influence of polymeric architecture on the delivery and anticancer effect of paclitaxel. , 2006, Bioconjugate chemistry.

[115]  K. Ulbrich,et al.  Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma. , 1994, British Journal of Cancer.

[116]  Hong Zhao,et al.  Novel prodrugs of SN38 using multiarm poly(ethylene glycol) linkers. , 2008, Bioconjugate chemistry.

[117]  R. Duncan,et al.  Preclinical toxicology of a novel polymeric antitumour agent: HPMA copolymerdoxorubicin (PK1) , 1998, Human & experimental toxicology.

[118]  M. Dewhirst,et al.  Thermal cycling enhances the accumulation of a temperature-sensitive biopolymer in solid tumors. , 2007, Cancer research.

[119]  E. Sausville,et al.  Targetable HPMA Copolymer–Aminohexylgeldanamycin Conjugates for Prostate Cancer Therapy , 2009, Pharmaceutical Research.

[120]  C. McCormick,et al.  Advances in the synthesis of amphiphilic block copolymers via RAFT polymerization: stimuli-responsive drug and gene delivery. , 2008, Advanced drug delivery reviews.

[121]  W. Hennink,et al.  Degradation Mechanism and Kinetics of Thermosensitive Polyacrylamides Containing Lactic Acid Side Chains , 2003 .

[122]  S. Beg,et al.  Dendrimers as novel systems for delivery of neuropharmaceuticals to the brain. , 2011, CNS & neurological disorders drug targets.

[123]  D. Kerr,et al.  Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. , 2009, International journal of oncology.

[124]  Y. Alnouti,et al.  Pharmacokinetic and biodistribution studies of N-(2-hydroxypropyl)methacrylamide copolymer-dexamethasone conjugates in adjuvant-induced arthritis rat model. , 2010, Molecular pharmaceutics.

[125]  Jinming Gao,et al.  Multifunctional Micellar Nanomedicine for Cancer Therapy , 2009, Experimental biology and medicine.

[126]  F. Roelfsema,et al.  Nanomedicines in the treatment of acromegaly: focus on pegvisomant , 2006, International journal of nanomedicine.

[127]  C. Allen,et al.  Poly(ethylene glycol)-b-poly(epsilon-caprolactone) micelles containing chemically conjugated and physically entrapped docetaxel: synthesis, characterization, and the influence of the drug on micelle morphology. , 2010, Biomacromolecules.

[128]  F. Szoka,et al.  Design, synthesis, and biological evaluation of a robust, biodegradable dendrimer. , 2010, Bioconjugate chemistry.

[129]  Tao Wang,et al.  Paclitaxel-loaded polymeric micelles modified with MCF-7 cell-specific phage protein: enhanced binding to target cancer cells and increased cytotoxicity. , 2010, Molecular pharmaceutics.

[130]  K. Ulbrich,et al.  Conjugates of doxorubicin with graft HPMA copolymers for passive tumor targeting. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[131]  A. Chilkoti,et al.  Temperature sensitive peptides: Engineering hyperthermia-directed therapeutics , 2008, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[132]  Lei Yu,et al.  Physicochemical properties and biocompatibility of a polymer-paclitaxel conjugate for cancer treatment , 2011, International journal of nanomedicine.

[133]  S. V. Vinogradov,et al.  Water-soluble block polycations as carriers for oligonucleotide delivery. , 1995, Bioconjugate chemistry.

[134]  K. Ulbrich,et al.  Preclinical evaluation of polymer-bound doxorubicin , 1992 .

[135]  L. Murray,et al.  Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[136]  R. Strickley Solubilizing Excipients in Oral and Injectable Formulations , 2004, Pharmaceutical Research.

[137]  K. Ulbrich,et al.  HPMA copolymer conjugates of paclitaxel and docetaxel with pH-controlled drug release. , 2010, Molecular pharmaceutics.

[138]  A. S. Moses,et al.  Imaging and drug delivery using theranostic nanoparticles. , 2010, Advanced drug delivery reviews.

[139]  Chi-Hwa Wang,et al.  Polymeric carriers for gene delivery: chitosan and poly(amidoamine) dendrimers. , 2010, Current pharmaceutical design.

[140]  T. Xu,et al.  Dendrimers as drug carriers: applications in different routes of drug administration. , 2008, Journal of pharmaceutical sciences.

[141]  A. Ray,et al.  Carboxyl-terminated PAMAM-SN38 conjugates: synthesis, characterization, and in vitro evaluation. , 2010, Bioconjugate chemistry.

[142]  S. Goldring,et al.  Novel dexamethasone-HPMA copolymer conjugate and its potential application in treatment of rheumatoid arthritis , 2007, Arthritis research & therapy.

[143]  H. Ghandehari,et al.  Targeting tumor angiogenic vasculature using polymer-RGD conjugates. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[144]  A. Chilkoti,et al.  Expression and purification of recombinant proteins from Escherichia coli: Comparison of an elastin‐like polypeptide fusion with an oligohistidine fusion , 2004, Protein science : a publication of the Protein Society.

[145]  Y. Yoshioka,et al.  The use of PVP as a polymeric carrier to improve the plasma half-life of drugs. , 2004, Biomaterials.

[146]  Yosuke Suzuki,et al.  Lactoferrin Conjugated with 40-kDa Branched Poly(ethylene Glycol) Has an Improved Circulating Half-Life , 2009, Pharmaceutical Research.

[147]  Allan S Hoffman,et al.  Poly(N-isopropylacrylamide-co-propylacrylic acid) copolymers that respond sharply to temperature and pH. , 2006, Biomacromolecules.

[148]  Thommey P. Thomas,et al.  Targeting and inhibition of cell growth by an engineered dendritic nanodevice. , 2005, Journal of medicinal chemistry.

[149]  J. Kopeček,et al.  Enantioselective release of 5-fluorouracil from N-(2-hydroxypropyl)methacrylamide-based copolymers via lysosomal enzymes. , 1995, Bioconjugate chemistry.

[150]  T. Okano,et al.  Preparation of micelle-forming polymer-drug conjugates. , 1992, Bioconjugate chemistry.

[151]  A. Ray,et al.  Anticancer and antiangiogenic activity of HPMA copolymer-aminohexylgeldanamycin-RGDfK conjugates for prostate cancer therapy. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[152]  L. Murray,et al.  Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours , 1999, British Journal of Cancer.

[153]  H. Zhao,et al.  20-O-acylcamptothecin derivatives: evidence for lactone stabilization. , 2000, The Journal of organic chemistry.

[154]  M. Graham Pegaspargase: a review of clinical studies. , 2003, Advanced drug delivery reviews.

[155]  K. Ulbrich,et al.  Poly(ethylene glycol) multiblock copolymer as a carrier of anti-cancer drug doxorubicin. , 2000, Bioconjugate chemistry.

[156]  Francesco M Veronese,et al.  Polyethylene glycol-superoxide dismutase, a conjugate in search of exploitation. , 2002, Advanced drug delivery reviews.

[157]  A. Seligman,et al.  Polyvinyl pyrrolidone as a plasma expander; studies on its excretion, distribution and metabolism. , 1952, The New England journal of medicine.

[158]  Z. Lu,et al.  Synthesis and characterization of HPMA copolymer-aminopropylgeldanamycin conjugates. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[159]  Wim E Hennink,et al.  Thermosensitive and biodegradable polymeric micelles for paclitaxel delivery. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[160]  Y. Ikada,et al.  Targeted delivery of anti-angiogenic agent TNP-470 using water-soluble polymer in the treatment of choroidal neovascularization. , 1999, Investigative ophthalmology & visual science.

[161]  Jan Jezek,et al.  Peptide and glycopeptide dendrimers and analogous dendrimeric structures and their biomedical applications , 2011, Amino Acids.

[162]  P. Okunieff,et al.  Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. , 1989, Cancer research.

[163]  P. Ofek,et al.  A novel antitumor prodrug platform designed to be cleaved by the endoprotease legumain. , 2009, Bioconjugate chemistry.

[164]  Donald A Tomalia,et al.  Dendrimers in biomedical applications--reflections on the field. , 2005, Advanced drug delivery reviews.

[165]  Chen Jiang,et al.  Gene delivery targeted to the brain using an Angiopep-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. , 2009, Biomaterials.

[166]  Ashutosh Chilkoti,et al.  Targeted drug delivery by thermally responsive polymers. , 2002, Advanced drug delivery reviews.

[167]  Todd Emrick,et al.  PEGylated polymers for medicine: from conjugation to self-assembled systems. , 2010, Chemical communications.

[168]  Veronese Fm,et al.  Introduction and overview of peptide and protein pegylation. , 2002 .

[169]  W. Hennink,et al.  Reduction-sensitive polymers and bioconjugates for biomedical applications. , 2009, Biomaterials.

[170]  I. Orienti,et al.  Modified Doxorubicin for Improved Encapsulation in PVA Polymeric Micelles , 2004, Drug delivery.

[171]  J. Kopeček,et al.  HPMA copolymers: origins, early developments, present, and future. , 2010, Advanced drug delivery reviews.

[172]  Markéta Jelínková,et al.  Starlike vs. Classic Macromolecular Prodrugs: Two Different Antibody-Targeted HPMA Copolymers of Doxorubicin Studied in Vitro and in Vivo as Potential Anticancer Drugs , 2003, Pharmaceutical Research.

[173]  C. Ryan,et al.  A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy , 2010, Anti-cancer drugs.

[174]  Gert Storm,et al.  Polymeric Micelles in Anticancer Therapy: Targeting, Imaging and Triggered Release , 2010, Pharmaceutical Research.

[175]  D. Wyss,et al.  Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. , 2002, Advanced drug delivery reviews.

[176]  M. Stenzel,et al.  The use of reversible addition fragmentation chain transfer polymerization for drug delivery systems , 2011, Expert opinion on drug delivery.

[177]  V. Torchilin,et al.  Structure and design of polymeric surfactant-based drug delivery systems. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[178]  J. Kopeček,et al.  Biodegradable Multiblock Poly[N-(2-hydroxypropyl)methacrylamide] via Reversible Addition-Fragmentation Chain Transfer Polymerization and Click Chemistry. , 2011, Macromolecules.

[179]  R. Kannan,et al.  Transfer of PAMAM dendrimers across human placenta: prospects of its use as drug carrier during pregnancy. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[180]  M. Brechbiel,et al.  Growing applications of "click chemistry" for bioconjugation in contemporary biomedical research. , 2009, Cancer biotherapy & radiopharmaceuticals.

[181]  K. Ulbrich,et al.  Biodegradable star HPMA polymer conjugates of doxorubicin for passive tumor targeting. , 2011, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[182]  Ruth Duncan,et al.  Anionic PAMAM Dendrimers Rapidly Cross Adult Rat Intestine In Vitro: A Potential Oral Delivery System? , 2000, Pharmaceutical Research.

[183]  Khaled Greish,et al.  Enhanced permeability and retention of macromolecular drugs in solid tumors: A royal gate for targeted anticancer nanomedicines , 2007, Journal of drug targeting.

[184]  J. Kopeček,et al.  Stability in rat plasma and serum of lysosomally degradable oligopeptide sequences in N-(2-hydroxypropyl) methacrylamide copolymers. , 1985, Biomaterials.

[185]  F. Kiessling,et al.  Macromolecular nanotheranostics for multimodal anticancer therapy. , 2011, Nanoscale.

[186]  K. Ulbrich,et al.  HPMA-based polymer conjugates with drug combination. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[187]  A. Pineda-Lucena,et al.  Polymer coiled-coil conjugates: potential for development as a new class of therapeutic "molecular switch". , 2011, Biomacromolecules.

[188]  Ashutosh Chilkoti,et al.  Purification of recombinant proteins by fusion with thermally-responsive polypeptides , 1999, Nature Biotechnology.

[189]  H. Byrne,et al.  Mechanistic studies of in vitro cytotoxicity of poly(amidoamine) dendrimers in mammalian cells. , 2010, Toxicology and applied pharmacology.

[190]  Zhongfan Jia,et al.  One-pot conversion of RAFT-generated multifunctional block copolymers of HPMA to doxorubicin conjugated acid- and reductant-sensitive crosslinked micelles. , 2008, Biomacromolecules.

[191]  Patricia Kraft,et al.  Novel Delivery of SN38 Markedly Inhibits Tumor Growth in Xenografts, Including a Camptothecin-11–Refractory Model , 2008, Clinical Cancer Research.

[192]  J. Leroux,et al.  Synthesis and Micellar Characterization of Novel Amphiphilic A−B−A Triblock Copolymers of N-(2-Hydroxypropyl)methacrylamide or N-Vinyl-2-pyrrolidone with Poly(ε-caprolactone) , 2002 .

[193]  T. Xu,et al.  Design, synthesis and potent pharmaceutical applications of glycodendrimers: a mini review. , 2007, Current drug discovery technologies.

[194]  K. Ulbrich,et al.  Biodegradable star HPMA polymer-drug conjugates: Biodegradability, distribution and anti-tumor efficacy. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[195]  Deborah S. Goldberg,et al.  Cellular Entry of G3.5 Poly (amido amine) Dendrimers by Clathrin- and Dynamin-Dependent Endocytosis Promotes Tight Junctional Opening in Intestinal Epithelia , 2010, Pharmaceutical Research.

[196]  V. Galic,et al.  Paclitaxel poliglumex for ovarian cancer , 2011, Expert opinion on investigational drugs.

[197]  Jeong Yu Lee,et al.  Intracellular delivery of paclitaxel using oil-free, shell cross-linked HSA--multi-armed PEG nanocapsules. , 2011, Biomaterials.

[198]  M. S. Tewart,et al.  Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. , 2000 .

[199]  D. Appelhans,et al.  In vivo toxicity of poly(propyleneimine) dendrimers. , 2011, Journal of biomedical materials research. Part A.